Key Sessions

Arthur Franken

Charting the Course: The 2024 Investment Landscape for European Biotechs

Gilde Healthcare

Susanne Kreutz

Prescription for Success: Navigating the Dynamic World of Pharma M&A in 2024

Novartis

Marta Lesko

Finding the “Golden Egg”: Forging Partnerships that Transform Technologies into Therapeutic Solutions

Merck

Holger Kissel

The Equation for Maturation: Biotech Requirements to Achieve Scale

BioNtech

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

08:00 - 09:00

REGISTRATION & BREAKFAST

Showing 3 of 3 Streams

BIOTECH LEADERS KEYNOTE PLENARY

MEDTECH LEADERS

HEALTHTECH LEADERS

09:00 - 09:05

LSX WELCOME ADDRESS

Adam Griffiths - Portfolio Manager, LSX Leaders

09:05 - 09:30

Assessing Biotech Investment Trends in 2024 And Beyond

Cody Powers - Partner, ZS Associates

09:30 - 10:30

Unveiling the Future - The Current Landscape and Spotlighting EU & UK Biotech and Pharma Excellence

Kate Bingham - Managing Partner, SV Health Investors
Sage Revell - Partner, Brown Rudnick
Ryan Richardson - Chief Strategy Officer, BioNTech
Laura Lane - Vice President, Lilly Ventures (Head of Europe), Eli Lilly
Tim Haines - Managing Director, Abingworth
Regina Hodits - Managing Partner, Wellington Partners

09:00 - 09:10

LSX WELCOME ADDRESS

Caitlin McNally - Conference Director- Medtech Lead, LSX

09:10 - 09:50

Keynote Panel: Elevating Global Recovery Through Strategic Partnerships

Hannah Musisi - International Healthcare Executive, UK
Stuart Hart - Chief Medical Officer, Integra Lifesciences
Jan Kimpen - Former CMO Philips, Venture Partner, Sanara Partners, Sanara Ventures
Kathleen Van Vlierberghe - VP Healthcare Solutions & Partnerships EMEA, Boston Scientific

09:50 - 10:30

How Are We Defining Innovation?

Gautam Kainth - Partner, The Capital Partnership
Isabelle Fourthin - VP Medical Affairs, Baxter
Antonio Sanchez-Cordero - Group Vice President, Strategy & Business Development (M&A), Speciality Diagnostics, Thermofisher
Jennifer Joe - Global Medical Strategy & Population Health Director, AstraZeneca
Mark Green - Senior Business Development & Strategy Director, Diabetes International, Medtronic
Ariana Adjani - Co-Founder & Managing Director, FINE TREATMENT

09:00 - 09:10

LSX WELCOME ADDRESS

Nadia Konneh - Senior Conference Director, Healthtech Lead, LSX

09:10 - 09:50

Future of Digital Health: How Can We Accelerate?

Emre Ozcan - VP, Global Head of Digital Health, Merck
Sridevi Nagarajan - Head Digital Regulatory Strategy, AstraZeneca
Soren Ostegaard - VP, Strategic Development & Digital Transformation, Global Drug Discovery, Novo Nordisk
Farnaz Behroozi - Head of Pharma, Huma
Nicolas Pivert - Senior Business Director, Cardiac Rhythm Management, Western Europe, Medtronic
Fraser Wood - Independent Digital Strategist (Former Global Incubator Lead, MSD), Independent

09:50 - 10:30

Balancing Patient-Centric Digital Therapeutics with Scalable Profitability

Marc Sluijs - Managing Partner, DigitalHealth.Network
Kamran Adle - VC Investor, Octopus Ventures
Hannes Klöpper - CEO, HelloBetter
Christian Lautner - Managing Partner, Heal Capital
Marek Ostrowski - Founder & CEO, Prosoma
Laura Wamprecht - Former Managing Director, Flying Health

10:30 - 11:10

MORNING BREAK

Showing 5 of 5 Streams

BIOTECH LEADERS - CAPITAL MARKETS & INVESTMENT

BIOTECH LEADERS - PARTNERSHIPS & DEAL MAKING

BIOTECH LEADERS - SCALING & COMMERCIALISATION

HEALTHTECH LEADERS

MEDTECH LEADERS

11:10 - 11:50

Charting the Course: The 2024 Investment Landscape for European Biotechs

Arthur Franken - Managing Partner, Gilde Healthcare
Woody Stileman - Managing Director, Strategic Partnerships, RTW Investments
Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners
Claire Brown - Investor, Oxford Science Enterprises
Natasha Barrow - Reporter, Citeline
Vanessa Carle - Senior Associate, Forbion

11:50 - 12:10

Fostering Biotech Innovation - A Perspective From Belgium's Ecosystem

Benoit Kenda - VP and Global Early Solution Partnering, Head, UCB
Amel Tounsi - CEO, Bridge 2 Health
Marc Foidart - CEO, EyED pharma

12:10 - 12:50

Navigating the Investment Frontier: Early-Stage Funding for Biotech Innovators

Daniela Begolo - Managing Director, EQT Life Sciences
Thomas Thestrup - Principal, Angelini Ventures
Clara Campàs Moya - Managing Partner & Cofounder, ASABYS PARTNERS
Sean Kendall - Principal, ARCH Venture Partners
Audrey Warner - Partner, TigerGene LLC
Alex Hamilton - Partner, Syncona

11:10 - 11:50

Striking Your Oncology Deal: New Partnering Approaches & Rethinking Innovation

Duncan Young - Executive Director, Oncology R&D Business Development, AstraZeneca
Sonal Patel - VP, Oncology Scientific Innovation, J&J Innovation
Chris Brown - Senior Director, Oncology BD, GSK
David Jenkins - Senior Vice President, Head of Research & External Innovation, Ipsen
Enda Gribbon - Director, Atelix

11:50 - 12:10

Novartis: Reimagining Medicine through Partnering

Adam Feire - Global Head Search & Evaluation, Corporate & Business Development, Novartis

12:10 - 12:50

Finding the “Golden Egg”: Forging Partnerships that Transform Technologies into Therapeutic Solutions

Marta Lesko - VP, Head of Neurology and Immunology Business Development, Merck
Bernd Nosse - Global Head BD&L Research Beyond Borders & Technologies, Boehringer Ingelheim
Bradley Hardiman - Senior Director, Scouting & Transaction - Business Development, Astellas Pharma Europe
Nerida Scott - Regional Head EMEA, J&J Innovation
Stefano Cottignoli - Head of Corporate Development, Chiesi Group
Ian Johnston - Global Pharmaceutical Correspondant, Financial Times

11:10 - 11:30

Commercial Models Of The Future And How The Biopharma Launch Landscape Is Changing

Ben Hohn - Principal, BD, Pipeline and Launch Strategy, ZS Associates

11:30 - 12:10

Commercial Models Of The Future And How The Biopharma Launch Landscape Is Changing: Expert Panel Discussion

Ben Hohn - Principal, BD, Pipeline and Launch Strategy, ZS Associates
Maria Törnsén - President, North America, Calliditas
John Butler - CEO, Akebia Therapeutics
Vered Bisker-Leib - CEO, Compass Therapeutics

12:10 - 12:50

Expanding Beyond Borders: The Role of BD in Scaling a Global Biotech

Frederic Scaerou - Head of Global Business Development, SERVIER
Sandra von Meier - Head of Business Development & Licensing, Debiopharm
Ragip Ziyal - Head of Coporate Development, Tillotts Pharma
Vishal Sahni - Director, Corporate Business Development & Strategy, H. Lundbeck A/S
Ian Mulvany - CTO, BMJ

11:10 - 12:00

Going Beyond the Hype - Exploring New Applications of AI/ML

Valerie Hepp - Digital and PHC Partnering Europe and Asia Lead, Roche
Szabolcs Nagy - Co-Founder, CEO, and Founder Director, Turbine
Yannis Pandis - Sr Director, AI, ML Analytics and Data Functional Lead, Pfizer
Colin Weller - General Manager, Evidence Generation Platform, Medable
Ian Mulvany - CTO, BMJ

12:00 - 12:50

Digital Health & DTx Partnerships – A Recipe For Success

Marko Kuisma - Partner, Innovestor
Gregoire Guillet - Chief Business and Value Officer, WeHealth Digital Medicine, Servier
Shahram Sharif - CEO, Liva Healthcare
Ashutosh Malhotra - Director, Digital Health Strategy & Partnerships, Europe, Daiichi Sankyo
Tina Tan - Executive Editor, FirstWord HealthTech

11:10 - 11:50

Innovation = Centralisation!? A Discussion About The Future Of Innovation In Medtech

Martin Witte - Senior Director Strategic Business Development, TÜV SÜD Product Service GmbH
Zubair Hussain - VP Regulatory, iSTAR
Susana de Azevedo Wӓsch - Vice President Quality Management, Regulatory Affairs & Medical Affairs, Ypsomed
Guido du Pree - Founder & CEO, Xyall
Ian Crosbie - CEO, Sequana Medical

11:50 - 12:10

Crossing the Valley of Death for Medical Devices

12:10 - 12:50

EU Market Entry - Demystifying Medical Device Reimbursement

Kai Nicol-Schwarz - Reporter, Sifted
Souad Belarbi - Governmental Affairs and Market Access Director, EU south and Indirect, Hologic
Max Ostermeier - CEO, Implandata Ophthalmic Products
Tuomas Neuvonen - CEO, Sooma Medical
Claartje Ypma - CEO, Augmedit

12:50 - 14:00

LUNCH BREAK

Showing 5 of 5 Streams

BIOTECH LEADERS - CAPITAL MARKETS & INVESTMENT

BIOTECH LEADERS - PARTNERSHIPS & DEAL MAKING

BIOTECH LEADERS - SCALING & COMMERCIALISATION

MEDTECH LEADERS

HEALTHTECH LEADERS

14:00 - 14:40

Accelerating Growth: Investment Strategies for Post Series B Biotech Ventures

Alastair Hugh Lowell Kilgour - Co-Founder & Chief Investment Officer, Parkwalk Advisors
Natalie Torin - Managing Director, Dunhill Ventures
Daniel Parera - Partner, Kurma Partners
Charles Conn - Managing Partner, Monograph Capital
Michael White - Head of Life Sciences, HSBC Innovation Bank, EMEA, HSBC
Alex Hamilton - Partner, Syncona

14:40 - 15:00

Tillotts with a Strong Track Record in Both Partnering and M&A: A Preferred Partner in Europe for Specialty Products

Ragip Ziyal - Head of Coporate Development, Tillotts Pharma

15:00 - 15:40

Public Biotech Playbook: Navigating the Current State of the Markets

Herve Kergrohen - Bioscience Focused Venture Partner, ABO
Max Klement - Principal, Novo Holdings
Ajan Reginald - CEO, Roquefort Therapeutics
John Rudy - Member / Co-chair, Securities & Capital Markets Practice, Mintz
Edouard Guillet - MD, IPF Partners

14:00 - 14:40

Cardiometabolic Disease & Obesity: Unlocking Unique Partnering Opportunities for Biotech

Ashley Zehnder - CEO, Fauna Bio
Alessandro Toniolo - Chief Executive Officer, Resalis Therapeutics
Peng Leong - Chief Business Officer & Head of Brain Aging, BioAge Labs
Steffen-Sebastian Bolz - CSO, Aphaia Pharma
Victoria English - Co-founder and Editor, MedNous

14:40 - 15:00

Debiopharm's Business Model – Developing Innovation Through Investing, Collaboration and Licensing

Sandra von Meier - Head of Business Development & Licensing, Debiopharm

15:00 - 15:40

Advancing CNS Treatments of Tomorrow Through Collaborative Partnerships

Jenny Barnett - CEO, Monument Tx
Jenny Laird - VP Search & Evaluation, Eli Lilly and Company
Kabir Nath - President and CEO, Compass Pathways
Olga Krylova - Head of S&E, Europe, Global Business Development & Innovation, Otsuka
Sahil Kirpekar - CBO, atai Life Sciences

14:00 - 14:40

The Equation for Maturation: Biotech Requirements to Achieve Scale

Holger Kissel - Senior Vice President Scientific Relations and Liaison, BioNtech
Celine Carlet - VP, Head of Transactions, Global BD, Galapagos
Bernd Muehlenweg - SVP Global Business Development, Evotec
Catherine Tucker - VP, Business Development, BenevolentAI

14:40 - 15:00

The Challenges of Scaling up: Learnings from 10 years of Evaluating R&D Productivity

Erika Kuchen - Head of Data-Science, Catenion
Alexander Wallroth - Strategy Consultant, Catenion

15:00 - 15:40

Achieving International Scale Through Accessing Cross Border Opportunities Within the Asia Pacific Market

Donald Xu - Managing Partner, Lynx Capital
Michelle Chen - Chief Business Officer, Insilico Medicine
Astrid Maria Dahl - COO and Head of Innovent Biologics (Europe), Innovent Biologics
Corinne Venot - Executive Director, Business Development, Beigene
James Wang - Head of BD, Adcendo

14:00 - 14:40

Investor Insights - Shaping Success for Early-Stage Ventures

Antoine D'Hollander - Investment Director, Capricorn Venture Partners
Jennifer McMahon - Partner, Sebora Life Sciences
Klaus Stöckemann - Managing Director & Co-Founder, Peppermint VenturePartners
Diana Saraceni - General Partner, Panakès Partners
Antoine Pau - Senior Partner, Truffle Capital
Gilad Peleg - Founding Partner, Neuro1 Capital

14:40 - 15:00

Peaks and Valleys - Unravelling the LimFlow Acquisition Journey

15:00 - 15:40

Burning Money - The Bottom-Line Impact of Neglecting Patients

Geoff Dobson - Non-Executive Director, Compass Executives
James Wong - Venture Partner, MedTech SuperConnector
Dan Cathie - CEO, Silveray
Anh Hoang - CEO, Jana Care
Zoe Chambers - Partner, Frontline Ventures

14:00 - 14:50

Navigating Pharma's Path To Launching Digital Health Products: Overcoming Challenges And Driving Innovation

Martin Alexander Gershon - Managing Partner & CIO, Endeavor Venture Fund
Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck
Christian Hein - Executive Advisor, Health Tech, Independent
Dominic James - Global Head of Digital Health Innovation & Alliances, MSD
Samantha Peacock - Senior Associate, Latham & Watkins

14:50 - 15:40

Embracing Digital Technologies & Scaling Patient-Centric Clinical Trials

Mats Berggren - Health Policy and Market Access, Merck
Aedan Martin - Global Information & Technology Business Partner, Roche
Marc Jones - CEO, Altoida
Andrew Mackinnon - Executive General Manager, Customer Value, Medable

15:40 - 16:20

AFTERNOON BREAK

Showing 3 of 3 Streams

BIOTECH LEADERS AFTERNOON KEYNOTE PLENARY

MEDTECH LEADERS

HEALTHTECH LEADERS

16:20 - 17:00

The Inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future

Renee Aguiar-Lucander - CEO, Calliditas Therapeutics
Deborah Sterling - Director, Sterne Kessler
Catherine Pickering - CEO, IOnctura
Carlos Buesa - CEO, Oryzon Genomics
Melissa Faris - CBO, OMass Therapeutics

17:00 - 17:40

Prescription for Success: Navigating the Dynamic World of Pharma M&A in 2024

Susanne Kreutz - Global Head, Corporate & Business Development, Novartis
Robbie McLaren - Partner, Latham & Watkins
Chris Sheldon - Senior Vice President, Head of Business Development, GSK
Matthias Müllenbeck - Senior Vice President, Head Global Business Development & Alliance Management, Merck KGaA
Stu Mackey - Global Head Business Development, Daichii-Sankyo
Keld Flintholm Jørgensen - SVP and Chief Business Officer, Lundbeck

16:20 - 17:00

Charting MedTech M&A: Strategies, Trends, and the Road Ahead

Roger Gunnarsson - Senior Advisor, Segulah Medical Accelaration
Tejas Atawane - Director Of Business Development, Philips
Alexander Roe - Senior Director, New Business Development, Intuitive
Sergio Levi - Chief Strategy and Business Officer, Nitinotes Surgical
Christian Schenk - Investment Director, Apposite Capital

17:00 - 17:40

Cultivating Success through CVC Partnerships in MedTech

Vivien De Tusch-Lec - General Partner, RYSE Asset Management
Andreas Wüpper - Managing Director, Fresenius Medical Care Ventures
Beatriz Almansa - Senior Associate, Philips Ventures
Anthony Vallance-Owen - Senior Investment Manager, Werfen
Vivian de Ruijter - Associate, Intuitive

16:20 - 17:00

Healthtech At Scale In Europe – Rising Above The Fragmented Digital Markets

Chris Hamilton - Partner, Global Head of Life Sciences, Odgers Berndtson
Lucy Jones - Chief Clinical Officer, Oviva
Ranjan Singh - Co-founder & CEO, HealthHero
Joao Barbosa da Silva - Senior Associate, re.Mind Capital
Klaudia Eriksson Philipp - Director, Global Digital Innovation & Alliances, Europe & US, Pfizer
Matthew Bardsley - Head of International, Telstra Health

17:00 - 17:40

Reality Check: DTX Investment Landscape, Still Hot or Cooling Down?

Shamik Parekh - Investor, Octopus Ventures
Ingrid Teigland Akay - Managing Partner, Hadean Ventures
Erki Mölder - Managing Partner, Verge Healthtech Fund
Josep Ll Sanfeliu - Managing Partner, Asabys Partners
Andy Molnar - CEO, Digital Therapeutics Alliance
Dominick Kennerson - SVP, HealthTech, HSBC Innovation Banking

17:40 - 19:45

CLOSE OF DAY 1 AGENDA – NETWORKING PARTY

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

Day 1 – Monday, 29 APRILMonday, 29 April 2024 - GMT (Greenwich Mean Time, GMTZ)

Get the Latest Event Updates